News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Nico Gagelmann: Ide-cel versus cilta-cel for relapsed or refractory multiple myeloma
Nico Gagelmann/X
Jan 19, 2025, 22:11

Nico Gagelmann: Ide-cel versus cilta-cel for relapsed or refractory multiple myeloma

Nico Gagelmann, Chair of the CAR-T for plasma cell disorder committee at The EBMT, shared a post on X about a recent paper by him and colleagues published in HemaSphere:

“Finally published!

Ide-cel versus cilta-cel for relapsed or refractory multiple myeloma.”

“Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study”

Authors: Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, Thomas Pabst, Nico Gagelmann et al.

Nico Gagelmann: Ide-cel versus cilta-cel for relapsed or refractory multiple myeloma

More posts featuring Nico Gagelmann.

Anca-Maria Albici Bastian von Tresckow cancer Maximilian Merz multiple myeloma Nico Gagelmann OncoDaily Oncology Thomas Pabst
Special Coverage
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era
Blog
Jan 19, 2025, 23:07
Antonio D'Alessio: Our work on neoadjuvant ICI in HCC has been chosen for the 2025 ASCO GI Merit Award
Science
Jan 19, 2025, 22:56
Bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab in pleural mesothelioma
Insight
Jan 19, 2025, 22:11
Nico Gagelmann: Ide-cel versus cilta-cel for relapsed or refractory multiple myeloma
Insight
Jan 19, 2025, 22:04
Chiaojung Jillian Tsai: TACE combined with Lenvatinib and Pembrolizumab vs Placebo for HCC
Insight
Jan 19, 2025, 22:02
FDA approved AstraZeneca’s Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma